中国医药：向专业投资者公开发行公司债券获注册批复

Core Viewpoint - The company has received approval from the China Securities Regulatory Commission to publicly issue corporate bonds totaling up to 2 billion yuan to professional investors [1] Group 1 - The company held its annual shareholder meeting in 2024, where it approved a proposal to register for corporate bonds and ultra-short-term financing bills [1] - The approval from the regulatory body allows the company to issue bonds with a total face value not exceeding 2 billion yuan, valid for 24 months from the date of approval [1] - The company has the option to issue the bonds in multiple tranches within the validity period of the registration [1]